Overview Dividends

(AMRN) Amarin - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: US0231114044

Omega-3, Cardiovascular, Prescription, Triglyceride, Vascepa

Biotechnology
Market Cap in USD: 290m
IPO / Inception: 1993-04-01
Return 12m vs S&P 500: 26.0%

EPS (Earnings per Share)

EPS (Earnings per Share) of AMRN over the last years for every Quarter: "2020-12": 0.01, "2021-03": -0.0041, "2021-06": 0.02, "2021-09": -0.03, "2021-12": 0.04, "2022-03": -0.08, "2022-06": -0.11, "2022-09": -0.01, "2022-12": 0.02, "2023-03": -0.04, "2023-06": -0.04, "2023-09": -0.05, "2023-12": -0.01, "2024-03": -0.02, "2024-06": 0.0037, "2024-09": -0.05, "2024-12": -0.02, "2025-03": -0.4, "2025-06": -0.03, "2025-09": -0.4,
EPS CAGR: -71.52%
EPS Trend: -49.8%
Last SUE: 1.77
Qual. Beats: 2

Revenue

Revenue of AMRN over the last years for every Quarter: 2020-12: 167.251, 2021-03: 142.17, 2021-06: 154.488, 2021-09: 142.038, 2021-12: 144.491, 2022-03: 94.63, 2022-06: 94.44, 2022-09: 89.878, 2022-12: 90.245, 2023-03: 85.975, 2023-06: 80.167, 2023-09: 66.056, 2023-12: 75.362931, 2024-03: 56.519, 2024-06: 67.56666, 2024-09: 42.298, 2024-12: 62.306, 2025-03: 42.017, 2025-06: 72.741, 2025-09: 48.558,
Rev. CAGR: -25.23%
Rev. Trend: -84.0%
Last SUE: 0.46
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 114%
Value at Risk 5%th 149%
Relative Tail Risk -20.14%
Reward TTM
Sharpe Ratio 0.87
Alpha 37.93
CAGR/Max DD -0.31
Character TTM
Hurst Exponent 0.540
Beta 0.970
Beta Downside 0.975
Drawdowns 3y
Max DD 81.74%
Mean DD 59.44%
Median DD 63.85%

Description: AMRN Amarin December 29, 2025

Amarin Corporation plc (NASDAQ: AMRN) is a Dublin-based biopharma that develops and commercializes cardiovascular therapeutics, most notably VASCEPA® (icosapent ethyl), a prescription-only omega-3 fatty-acid drug used to lower triglycerides in patients with severe hypertriglyceridemia. The company distributes primarily through wholesale and specialty-pharmacy channels in the United States, Europe, and other international markets, and it maintains a development partnership with Japan’s Mochida Pharmaceutical to explore additional EPA-based indications.

Key recent metrics: FY 2023 VASCEPA net sales fell to roughly $1.0 billion, reflecting the loss of Medicare Part D coverage for the cardiovascular-risk reduction indication in 2022; however, a 2023 FDA label expansion reinstated the drug’s use for secondary prevention, which could re-ignite demand. The global prescription omega-3 market is projected to grow at a CAGR of ~5 % through 2028, driven by an aging population and rising prevalence of metabolic syndrome, while reimbursement uncertainty remains a primary headwind for Amarin’s revenue outlook.

For a data-driven assessment of AMRN’s valuation and risk profile, you may find the analytics on ValueRay worth a quick look.

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-86.2m TTM) > 0 and > 6% of Revenue (6% = 13.5m TTM)
FCFTA -0.03 (>2.0%) and ΔFCFTA -0.86pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 197.7% (prev 185.6%; Δ 12.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.03 (>3.0%) and CFO -21.9m > Net Income -86.2m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (415.5m) change vs 12m ago 1.07% (target <= -2.0% for YES)
Gross Margin 39.06% (prev 55.85%; Δ -16.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 31.99% (prev 32.21%; Δ -0.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -7894 (EBITDA TTM -52.2m / Interest Expense TTM 7000 ) >= 6 (WARN >= 3)

Altman Z'' -11.82

(A) 0.68 = (Total Current Assets 628.3m - Total Current Liabilities 182.2m) / Total Assets 659.8m
(B) -2.59 = Retained Earnings (Balance) -1.71b / Total Assets 659.8m
warn (B) unusual magnitude: -2.59 — check mapping/units
(C) -0.08 = EBIT TTM -55.3m / Avg Total Assets 705.2m
(D) -6.95 = Book Value of Equity -1.40b / Total Liabilities 200.9m
Total Rating: -11.82 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 20.14

1. Piotroski 0.50pt
2. FCF Yield data missing
3. FCF Margin -9.69%
4. Debt/Equity 0.01
5. Debt/Ebitda 2.22
6. ROIC - WACC (= -21.71)%
7. RoE -18.30%
8. Rev. Trend -83.95%
9. EPS Trend -49.76%

What is the price of AMRN shares?

As of January 09, 2026, the stock is trading at USD 16.40 with a total of 250,519 shares traded.
Over the past week, the price has changed by +19.53%, over one month by +9.92%, over three months by -14.94% and over the past year by +49.09%.

Is AMRN a buy, sell or hold?

Amarin has received a consensus analysts rating of 2.33. Therefor, it is recommend to sell AMRN.
  • Strong Buy: 0
  • Buy: 0
  • Hold: 1
  • Sell: 2
  • Strong Sell: 0

What are the forecasts/targets for the AMRN price?

Issuer Target Up/Down from current
Wallstreet Target Price 12 -26.8%
Analysts Target Price 12 -26.8%
ValueRay Target Price 14.5 -11.3%

AMRN Fundamental Data Overview January 02, 2026

P/E Forward = 500.0
P/S = 1.2798
P/B = 0.6323
P/EG = -1.74
Beta = 0.715
Revenue TTM = 225.6m USD
EBIT TTM = -55.3m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 6.73m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 6.73m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.1m USD (from netDebt column, last quarter)
Enterprise Value = 10.3m USD (290.2m + Debt 6.73m - CCE 286.6m)
Interest Coverage Ratio = -7894 (Ebit TTM -55.3m / Interest Expense TTM 7000 )
FCF Yield = -212.1% (FCF TTM -21.9m / Enterprise Value 10.3m)
FCF Margin = -9.69% (FCF TTM -21.9m / Revenue TTM 225.6m)
Net Margin = -38.20% (Net Income TTM -86.2m / Revenue TTM 225.6m)
Gross Margin = 39.06% ((Revenue TTM 225.6m - Cost of Revenue TTM 137.5m) / Revenue TTM)
Gross Margin QoQ = 45.73% (prev 69.23%)
Tobins Q-Ratio = 0.02 (Enterprise Value 10.3m / Total Assets 659.8m)
Interest Expense / Debt = 0.10% (Interest Expense 7000 / Debt 6.73m)
Taxrate = -5.12% (negative due to tax credits) (377.0k / -7.36m)
NOPAT = -58.1m (EBIT -55.3m * (1 - -5.12%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.45 (Total Current Assets 628.3m / Total Current Liabilities 182.2m)
Debt / Equity = 0.01 (Debt 6.73m / totalStockholderEquity, last quarter 458.9m)
Debt / EBITDA = 2.22 (negative EBITDA) (Net Debt -116.1m / EBITDA -52.2m)
Debt / FCF = 5.31 (negative FCF - burning cash) (Net Debt -116.1m / FCF TTM -21.9m)
Total Stockholder Equity = 470.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.22% (Net Income -86.2m / Total Assets 659.8m)
RoE = -18.30% (Net Income TTM -86.2m / Total Stockholder Equity 470.9m)
RoCE = -11.57% (EBIT -55.3m / Capital Employed (Equity 470.9m + L.T.Debt 6.73m))
RoIC = -12.34% (negative operating profit) (NOPAT -58.1m / Invested Capital 470.9m)
WACC = 9.38% (E(290.2m)/V(296.9m) * Re(9.59%) + D(6.73m)/V(296.9m) * Rd(0.10%) * (1-Tc(-0.05)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.86%
Fair Price DCF = unknown (Cash Flow -21.9m)
EPS Correlation: -49.76 | EPS CAGR: -71.52% | SUE: 1.77 | # QB: 2
Revenue Correlation: -83.95 | Revenue CAGR: -25.23% | SUE: 0.46 | # QB: 0
EPS next Year (2026-12-31): EPS=0.59 | Chg30d=+0.440 | Revisions Net=+1 | Growth EPS=+168.2% | Growth Revenue=-18.7%

Additional Sources for AMRN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle